person · Reporting owner
MCGRAW BENJAMIN F III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evommune, Inc.EVMN · Entity 5539 | Director | June 02, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evommune, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.82 · Expires 2036-06-01 | Direct | 15,673 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 15,673 · Balance 15,673 F1: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date November 21, 2022 · Filed November 21, 2022
Section 16 reporting ended · disclosed 2022-11-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 1
1 source rowRow 1 · 2022-11-21 · Disposition to issuer · Disposed 41,984 · Balance 0 F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.27 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.59 · Expires 2031-09-20 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-21 · Disposition to issuer · Disposed 102,412 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2022-11-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-21 · Disposition to issuer · Disposed 16,854 · Balance 0 F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.
F2: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 4, 2026 00:04 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantStock Option (Right to buy) · Derivative | 15,673 | $0.00 Strike: $19.82 | $0.00 |
DisclosureSEC source: 0001216994-26-000003 · primarydocument.xml · derivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,673 Underlying: Common Stock · 15,673 shares Expires 2036-06-01 F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:15 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantStock Option (Right to Buy) · Derivative | 37,960 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001216994-25-000008 · form4-11072025_041110.xml · derivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,960 Underlying: Common Stock · 37,960 shares Expires 2035-11-04 F1 · derivative.exercise_date: One third (1/3) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:57 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerStock Option (right to buy) · Derivative | 16,854 | $9.14 Strike: $6.11 | $154,045.56 |
DisclosureSEC source: 0001209191-22-058189 · doc4.xml · derivative · entry 4 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,854 shares Expires 2032-06-09 F2 · kind: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. F2 · derivative.exercise_date: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:57 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerStock Option (right to buy) · Derivative | 102,412 | $3.66 Strike: $11.59 | $374,827.92 |
DisclosureSEC source: 0001209191-22-058189 · doc4.xml · derivative · entry 3 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,412 shares Expires 2031-09-20 F2 · kind: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. F2 · derivative.exercise_date: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:57 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerStock Option (right to buy) · Derivative | 7,800 | $1.98 Strike: $13.27 | $15,444.00 |
DisclosureSEC source: 0001209191-22-058189 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,800 shares Expires 2030-06-11 F2 · kind: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. F2 · derivative.exercise_date: Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 21:57 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Disposition to issuerCommon Stock | 41,984 | $15.25 | $640,256.00 |
DisclosureSEC source: 0001209191-22-058189 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:18 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 16,854 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001209191-22-036397 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,854 Underlying: Common Stock · 16,854 shares Expires 2032-06-09 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 9, 2022. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:18 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 6,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036397 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,984 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 9, 2023. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Tax withholdingCommon Stock | 10,324 | $8.30 | $85,689.20 |
DisclosureSEC source: 0001209191-22-014974 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director · Interim Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,739 F1 · shares: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:40 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 102,412 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-21-057288 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director · Interim Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,412 Underlying: Common Stock · 102,412 shares Expires 2031-09-20 F2 · derivative.exercise_date: Subject to the reporting person's continued service as Interim Executive Chair through the vesting date, this option is scheduled to vest on the earliest of (i) March 17, 2021 and (ii) the date on which the reporting person's service as Interim Executive Chair ceases following the company's appointment of a new CEO. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:40 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 34,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057288 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director · Interim Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,063 F1 · shares: Subject to the reporting person's continued service as Interim Executive Chair through the vesting date, these shares of Common Stock are scheduled to vest on the earliest of (i) March 17, 2021 and (ii) the date on which the reporting person's service as Interim Executive Chair ceases following the company's appointment of a new CEO. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-21-042031 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-06-17 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 17, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042031 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,550 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 17, 2022. Read SEC document |
| June 11, 2020 Filed Jun 30, 2020 00:02 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0001209191-20-039260 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2030-06-11 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 11, 2020. Read SEC document |
| June 11, 2020 Filed Jun 30, 2020 00:02 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039260 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,800 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 11, 2021. Read SEC document |
| May 23, 2019 Filed May 23, 2019 22:14 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $39.44 | $0.00 |
DisclosureSEC source: 0001209191-19-032435 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2029-05-23 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of May 23, 2019. Read SEC document |
| May 23, 2019 Filed May 23, 2019 22:14 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032435 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on May 23, 2020. Read SEC document |
| June 07, 2018 Filed Jun 9, 2018 00:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 7,800 | $0.00 Strike: $65.15 | $0.00 |
DisclosureSEC source: 0001209191-18-036813 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2028-06-07 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 7, 2018. Read SEC document |
| June 07, 2018 Filed Jun 9, 2018 00:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036813 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 7, 2019. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $52.85 | $0.00 |
DisclosureSEC source: 0001209191-17-038857 · doc4.xml · derivative · entry 2 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-08 F2 · derivative.exercise_date: Subject to the reporting person's continued service on the board of directors of the issuer through the applicable vesting date, this option is scheduled to vest ratably on each of the first 12 monthly anniversaries of June 8, 2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-038857 · doc4.xml · nonDerivative · entry 1 MCGRAW BENJAMIN F III · CIK 0001216994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,550 F1 · shares: Subject to the reporting person's continued service on the board of directors of the issuer through the vesting date, these shares of Common Stock are scheduled to vest on June 8, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.